IFNA2 and chronic myelogenous leukemia, BCR-ABL1 positive: IFN-α was one of the earliest treatments for chronic myeloid leukemia that was shown to prolong 5-year overall survival (OS) compared to conventional chemotherapy (50–59% with IFN-α compared to 29–44% with busulfan or hydroxyurea) [45,46,47].